Landmark CRISPR trial shows promise against deadly disease

Administering gene-editing treatment directly into the body could be a safe and effective way to treat a rare, life-threatening condition. Preliminary results from a landmark clinical trial suggest that CRISPR–Cas9 gene editing can be deployed directly into the body to treat disease.

The study is the first to show that the technique can be safe and effective if the CRISPR–Cas9 components — in this case targeting a protein that is made mainly in the liver — are infused into the bloodstream. In the trial, six people with a rare and fatal condition called transthyretin amyloidosis received a single treatment with the gene-editing therapy. All experienced a drop in the level of a misshapen protein associated with the disease. Those who received the higher of two doses tested saw levels of the protein, called TTR, decline by an average of 87%.

Deplancke lab – Laboratory of Systems Biology and Genetics

(v.l.n.r.) Lothar Jäckel, Lisa Schneider, Angelika Offinger, Emilia Terszowska, Sabine Eckervogt, Yasmin Müller-Quijada und Michel Brühlhart. Nicht auf dem Bild: Vanessa Schull, Johann Himber, Brice Herbrecht und Daniel-Uwe Zimmer. (Bild: Rolf Zeller)

Auszeichnung für Tierpflegende für die Verminderung überzähliger Versuchstiere

Bei einer LAMA2-Muskeldystrophie fehlt den Muskelzellen ein stabilisierender Faktor. Forschende haben eine vielversprechende Gentherapie entwickelt, um Abhilfe zu schaffen. (Symbolbild: Adobe Stock)

Seltene Muskelkrankheit: Seehund hilft Lama

Suchalgorithmus enthüllt fast 200 neue Arten von CRISPR-Systemen

CRISPR/Cas bei Pflanzen: Was die Gen-Schere kann - und was (noch) nicht

Grün, blau und rot eingefärbte Blasentumor-Organoide.

Mit einem Tumor-Avatar gezielter gegen Blasenkrebs